315 related articles for article (PubMed ID: 15014023)
1. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.
Konecny GE; Meng YG; Untch M; Wang HJ; Bauerfeind I; Epstein M; Stieber P; Vernes JM; Gutierrez J; Hong K; Beryt M; Hepp H; Slamon DJ; Pegram MD
Clin Cancer Res; 2004 Mar; 10(5):1706-16. PubMed ID: 15014023
[TBL] [Abstract][Full Text] [Related]
2. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract][Full Text] [Related]
3. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ
J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347
[TBL] [Abstract][Full Text] [Related]
4. [Study of the correlation between HER-2 gene and lymphangiogenesis and their prognostic significance in human breast cancer].
Zhang GH; Yang WT; Zhou XY; Zeng Y; Lu HF; Shi DR
Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(3):155-60. PubMed ID: 17425844
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.
Gasparini G; Toi M; Gion M; Verderio P; Dittadi R; Hanatani M; Matsubara I; Vinante O; Bonoldi E; Boracchi P; Gatti C; Suzuki H; Tominaga T
J Natl Cancer Inst; 1997 Jan; 89(2):139-47. PubMed ID: 8998183
[TBL] [Abstract][Full Text] [Related]
6. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
Harbeck N; Ross JS; Yurdseven S; Dettmar P; Pölcher M; Kuhn W; Ulm K; Graeff H; Schmitt M
Int J Oncol; 1999 Apr; 14(4):663-71. PubMed ID: 10087312
[TBL] [Abstract][Full Text] [Related]
7. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up.
Nakamura Y; Yasuoka H; Tsujimoto M; Yang Q; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K
Clin Cancer Res; 2003 Feb; 9(2):716-21. PubMed ID: 12576440
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
10. Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1alpha (HIF-1alpha)-related expression of vascular endothelial growth factor (VEGF) in cancer cells overexpressing her-2/neu oncogene.
Menendez JA; Vellon L; Oza BP; Lupu R
J Cell Biochem; 2005 Apr; 94(5):857-63. PubMed ID: 15669079
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.
Kim YS; Konoplev SN; Montemurro F; Hoy E; Smith TL; Rondón G; Champlin RE; Sahin AA; Ueno NT
Clin Cancer Res; 2001 Dec; 7(12):4008-12. PubMed ID: 11751494
[TBL] [Abstract][Full Text] [Related]
12. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy.
Têtu B; Brisson J
Cancer; 1994 May; 73(9):2359-65. PubMed ID: 7909490
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas.
Li Q; Wang D; Li J; Chen P
BMC Cancer; 2011 Jun; 11():277. PubMed ID: 21708009
[TBL] [Abstract][Full Text] [Related]
15. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
[TBL] [Abstract][Full Text] [Related]
18. Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression.
Lee JS; Kim HS; Jung JJ; Kim YB; Lee MC; Park CS
Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):289-95. PubMed ID: 12607595
[TBL] [Abstract][Full Text] [Related]
19. Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients.
Tokatli F; Altaner S; Uzal C; Ture M; Kocak Z; Uygun K; Bilgi S
Exp Oncol; 2005 Jun; 27(2):145-9. PubMed ID: 15995634
[TBL] [Abstract][Full Text] [Related]
20. HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer.
Konecny G; Fritz M; Untch M; Lebeau A; Felber M; Lude S; Beryt M; Hepp H; Slamon D; Pegram M
Breast Cancer Res Treat; 2001 Sep; 69(1):53-63. PubMed ID: 11759828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
